10.1038/ng.325 [DOI] [PMC free article] [PubMed] [Google Scholar] 28.Baez-Duarte BG, Zamora-Ginez I, Mendoza-Carrera F, Ruiz-Vivanco G, Torres-Rasgado E, Gonzalez-Mejia ME, et al
N.LewisS.QuinnellR.MinhT
Efficacy and safety of co-administered once-weekly cagrilintide 24 mg with once-weekly semaglutide 24 mg in type 2 diabetes. Lancet 402(10403):720730
*Correspondence: Alja Zottel, [email protected] These authors share senior authorship Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
The first sub-analysis involved stratifying patients based on their AHM initiation status: newly-initiated users (patients who started AHMs on or after January 1, 2011, with no prior recorded use) and prevalent users (patients with a history of AHM use before January 1, 2011)